Brain Tumor Diagnosis And Therapeutics Market Size, Share & Trends Analysis Report By Type, By Product (Stains & Varnishes, Shellacs), By Diagnosis, By Therapeutics, By End-use, By Region, And Segment Forecasts, 2024 - 2030

Market Size & Trends

The global brain tumor diagnosis and therapeutics market size was valued at USD 3.11 billion in 2023 and is projected to grow at a CAGR of 7.1% from 2024 to 2030. The growing launches of brain tumor therapeutics products and the rise in cancer awareness for brain tumor medications drive the market over the forecast period.

Improved imaging techniques, such as CT scans and MRIs, facilitate early and accurate diagnosis of brain tumors. Ongoing research and improvement efforts have led to centered therapies, immunotherapies, and customized medicine, improving the effectiveness and specificity of brain tumor treatment. Minimally invasive surgical techniques, such as stereotactic radiosurgery and endoscopic neurosurgery, enhance patient conditions and optimize recovery times.

The rise in the geriatric population is one of the factors contributing to market growth. Increasing awareness about early diagnosis, regulatory approvals for new tablets and treatments, and favorable reimbursement policies enable advanced treatments for patients. Significant investments by pharmaceutical and biotechnology companies, followed by government and private companies spending on innovation, are driving the improvement of new therapeutics and the exploration of advanced treatment modalities such as gene therapy and nanotechnology.

Type Insights

The primary segment dominated the brain tumor diagnosis & therapeutics market with a revenue share of 62.7% in 2023. Primary brain tumors encompass a wide range, including meningioma, gliomas, astrocytes, and pituitary tumors. Each requires specific diagnostic treatment, leading to diverse diagnoses and therapies. Technological advancements and treatments improve the patient’s experience with primary brain tumors. The increasing emphasis on personalized medicine and patient-centric approaches drives market growth.

The secondary segment is expected to grow at the fastest CAGR of 6.8% over the forecast period. This type of tumor is more common than the primary brain tumor, as it grows in other parts of the body. Advancements in imaging technologies have improved the detection of secondary brain tumors, such as MRI and CT scans. As the population ages, there is a corresponding increase in secondary brain tumors, which fuels the need for brain tumor diagnosis and therapeutics. In addition, increased awareness about the symptoms and early detection allows early access to the therapy and diagnosis.

Product Insights

The stains & varnishes segment dominated with a market share of 25.7% in 2023. Stains & varnishes assist pathologists in visualizing cell structures with a microscope in identifying tumor cells. Pathologists can differentiate distinct cellular sorts within a tumor using particular stains, which are crucial for determining its nature and aggressiveness. In addition, staining strategies assess tumor grade, which is important for determining the ideal treatment strategy for patients with brain tumors.

The shellac segment is expected to register the fastest CAGR of 6.6% in the forecast period. Shellac nanoparticles can encapsulate tablets and supply them specifically to brain tumor cells. This focused drug delivery system complements the efficacy of the treatment by minimizing the side effects on healthy tissue. Shellacs use CT scans for imaging brain tumors, and MRIs help with accurate diagnosis, enabling healthcare professionals to make informed treatment decisions. Shellacs are biodegradable and biocompatible and are thus, ideal for medical programs.

Diagnosis Insights

CT scan dominated the diagnosis segment in the brain tumor diagnosis & therapeutics market, with a revenue share of 25.6% in 2023. It offers high accuracy in detecting brain tumors. Imaging technologies provide precise brain images, allowing healthcare specialists to accurately perceive the location, size, and tumor characteristics. CT scan is preferred over traditional approaches such as biopsies because CT scan is easy to perform without any life threats. In addition, CT scan diagnosis allows early detection of tumors, enabling healthcare professionals to initiate interventions during surgery, radiation therapy, and chemotherapy, among others.

The cerebral arteriogram segment is expected to register a CAGR of 8.4% in the forecast period. Cerebral arteriograms assist in correctly localizing brain tumors with the help of mapping out the blood vessels that supply the tumor. This is crucial for surgical planning and determining the feasibility of tumor removal. In addition, accurately locating the arteries that feed into a brain tumor is important for formulating targeted treatment strategies with embolization or selective chemotherapy delivery. Cerebral arteriograms offer special insights into these feeding arteries.

Therapeutics Insights

The surgery segment in therapeutics dominated the market with a revenue share of 35.7% in 2023. Surgery is often the preferred initial treatment while removing tumors with this method surgeon can remove several tumors as possible. For instance, if the tumor is in deep places or crucial areas, a surgical procedure addresses the affected areas. The growth of the surgery segment can be attributed to its precision in tumor elimination, capacity to provide tissue samples for accurate analysis, role in debulking and symptom relief, and capacity for personalized treatment techniques.

Targeted therapy is expected to register a CAGR of 7.7% in the forecast period. Targeted therapy gives a precise medical drug method, identifying unique molecular targets specific to cancer cells. This customized treatment approach has resulted in powerful and centered treatment of brain tumors while minimizing harm to healthy cells. In addition, targeted therapy drives market growth through its improved efficiency, reduced side effects, resistance mitigation capabilities, and advances in molecular profiling techniques.

End-use Insights

The oncology treatment centers segment dominated the market with a revenue share of 48.7% in 2023. Oncology treatment centers are committed facilities that specialize in the diagnosis and treatment of cancer, along with brain tumors. These facilities commonly have a healthcare professional with a specialized understanding of oncology, neurology, neurosurgery, radiation oncology, and related fields. The specialization enables them to offer complete and personalized care to patients with brain tumors. The segment’s growth is attributed to access to advanced technology, patient care approaches, and continuous research and development.

The hospital segment is expected to register the fastest growth rate of 6.0% over the forecast period. Hospitals play a pivotal role in the treatment and offer comprehensive services with high-tech devices such as MRIs & CT scans. In addition, hospital settings allow the population to access healthcare facilities with a wide range of treatment options for ailments and disorders. Moreover, collaboration with academic institutes and research facilities with technological innovation and devices has enhanced the hospital facilities.

Regional Insights

North America dominated the global brain tumor diagnosis and therapeutics market with a revenue share of 41.8% in 2023. Developed healthcare infrastructure, significant per capita spending, and awareness regarding early diagnosis drive market growth in North America. In addition, factors such as the rise in geriatric population, and collaboration between government and private companies to invest in clinical technologies assist the segment growth.

U.S. Brain Tumor Diagnosis and Therapeutics Market Trends

U.S. brain tumor diagnosis & therapeutics market dominated the North American regional market with a revenue share of 88.3% in 2023. This dominance can be attributed to the growing infrastructure facilities and awareness regarding advanced technology and clinical solutions.

Europe Brain Tumor Diagnosis and Therapeutics Market Trends

Europe brain tumor diagnosis & therapeutics market held a market share of 26.4% in 2023. The technological improvements, growing prevalence of brain tumors, rising awareness about early diagnosis, and favorable reimbursement policies propel the need for therapies. These elements together contribute to a high-quality outlook for the market as it continues to cater to healthcare needs associated with brain tumors.

The UK brain tumor diagnosis & therapeutics market is expected to grow rapidly in the coming years due to the rise in the number of patients with brain tumors, and an increase in the geriatric population. Government initiatives regarding awareness and access to advanced surgical procedures drive market growth.

Germany brain tumor diagnosis & therapeutics market held a substantial share in 2023 due to the growing healthcare infrastructure, and the preference for minimally invasive surgical approaches among patients because of their low-risk factors, and effective recuperation. This trend has fueled the demand for minimally invasive treatment for brain tumors in Germany.

Asia Pacific Brain Tumor Diagnosis and Therapeutics Market Trends

Asia Pacific brain tumor diagnosis & therapeutics market is expected to register a CAGR of 8.3% in the forecast period. This is due to an increasing incidence of glioblastomas in the aging population, changes in lifestyle, and advanced diagnostic techniques that have contributed to the detection of brain tumors inside the region. In addition, research and development activities have innovated new therapies for brain tumors.

China brain tumor diagnosis & therapeutics market is expected to grow more in the coming years due to the increasing prevalence of brain tumors, technological advancements, modern therapies, rise in healthcare expenditure, and awareness campaigns that collectively contribute to market growth.

India brain tumor diagnosis & therapeutics market held a substantial share in 2023 due to the rise in healthcare expenditure, the geriatric population, and an increasing prevalence of brain tumors. The government's objectives toward improving healthcare infrastructure and access to better healthcare services have played a significant role in driving market growth in India.

Key Brain Tumor Diagnosis And Therapeutics Company Insights

Some key companies in the brain tumor diagnosis and therapeutics market include Amgen Inc.; AstraZeneca; Bayer AG; GE HealthCare.; F. Hoffmann-La Roche Ltd; Eisai Co., Ltd.; and others. Organizations focus on increasing their customer base to gain a competitive edge in the industry. Therefore, key players are undertaking several strategic initiatives, such as mergers and acquisitions, and partnerships with other major companies. 

• AstraZeneca is a leading international biopharmaceutical company. The organization emphasizes the power of technology and innovation in driving improvements in the medical sector. AstraZeneca explores various therapeutic regions to discover new treatments and improve existing ones, with a huge product pipeline.

• Bayer AG is a German multinational pharmaceutical and biotechnology company in healthcare and agriculture. Bayer AG continues to focus on research and developments to convey innovation and technologies to the market for healthcare and agriculture. The company markets its products globally through diverse channels with wholesalers, pharmacies, hospitals, and retailers.

Recent Developments

• In March 2024, AstraZeneca acquired Fusion to accelerate developments in cancer treatments. The acquisition focuses on replacing traditional treatments such as chemotherapy and radiotherapy with a modernized approach.

• In January 2024, GE HealthCare acquired MIM Software. This agreement facilitates MIM software with AI-enabled imaging and workflow tools across various sectors such as oncology, and neurology healthcare sectors.

Brain Tumor Diagnosis And Therapeutics Market Report Scope

Global Brain Tumor Diagnosis And Therapeutics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global brain tumor diagnosis and therapeutics market report based on type, product, diagnosis, therapeutics, end-use, and region.

• Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Primary

    • Meningioma

    • Gliomas

    • Astrocytomas

    • Pituitary Tumors

    • Others

  • Secondary

• Product Outlook (Revenue, USD Million, 2018 - 2030)

  • Stains & Varnishes

  • Shellacs

  • Lacquers

  • Others

• Diagnosis Outlook (Revenue, USD Million, 2018 - 2030)

  • MRI

  • CT-Scan

  • Tissue Sampling

  • PET-CT Scan

  • Cerebral Arteriogram

  • Lumbar Puncture

  • Molecular Testing

  • EEG

  • Others

• Therapeutics Outlook (Revenue, USD Million, 2018 - 2030)

  • Surgery

  • Radiation Therapy

  • Chemotherapy

  • Immunotherapy

  • Targeted Therapy

  • Others

• End Use Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospitals

  • Oncology Treatment Centers

  • Others

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait